Rockwell Medical Inc (RMTI) : Strid Group added new position in Rockwell Medical Inc during the most recent quarter end. The investment management firm now holds 11,000 shares of Rockwell Medical Inc which is valued at $89,210 , the company said in a statement filed on Jul 25, 2016 with the SEC.Rockwell Medical Inc makes up approximately 0.04% of Strid Group’s portfolio.
Other Hedge Funds, Including , Msi Financial Services Inc added RMTI to its portfolio by purchasing 3,500 company shares during the most recent quarter which is valued at $28,385. Mizuho Securities Usa sold out all of its stake in RMTI during the most recent quarter. The investment firm sold 63,400 shares of RMTI which is valued $505,932. Lowe Fs sold out all of its stake in RMTI during the most recent quarter. The investment firm sold 15,735 shares of RMTI which is valued $125,565.Balasa Dinverno Foltz reduced its stake in RMTI by selling 2,000 shares or 5.29% in the most recent quarter. The Hedge Fund company now holds 35,800 shares of RMTI which is valued at $278,882. Rockwell Medical Inc makes up approx 0.05% of Balasa Dinverno Foltz’s portfolio.
Rockwell Medical Inc closed down -0.05 points or -0.62% at $8.05 with 1,76,715 shares getting traded on Friday. Post opening the session at $8.09, the shares hit an intraday low of $7.9842 and an intraday high of $8.14 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Rockwell Medical Inc reported $-0.10 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.12. The company had revenue of $13.63 million for the quarter, compared to analysts expectations of $15.65 million. The company’s revenue was down -1.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.07 EPS.
Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.